Phathom Pharmaceuticals, Inc. EPS (Diluted)

EPS (Diluted) of PHAT for past 10 years: annual, quarterly and twelve month trailing (TTM) including EPS (Diluted) growth rates and interactive chart. Diluted earnings per share (EPS) tells investors how much of a firm's net income was allotted to each share of common stock. It is reported in a company's income statement and is especially informative for businesses with only common stock in their capital structures. Calculated as net income to common divided by the weighted average number of diluted shares outstanding (takes into account potential dilution from options or share issuance).


Highlights and Quick Summary

  • EPS (Diluted) for the quarter ending September 29, 2021 was -0.98 (a -2.0% decrease compared to previous quarter)
  • Year-over-year quarterly EPS (Diluted) decreased by -37.97%
  • Annual EPS (Diluted) for 2020 was -3.88 (a -82.72% decrease from previous year)
  • Annual EPS (Diluted) for 2019 was -22.45 (a 44800.0% increase from previous year)
Visit stockrow.com/PHAT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical EPS (Diluted) of Phathom Pharmaceuticals, Inc.

Most recent EPS (Diluted)of PHAT including historical data for past 10 years.

Interactive Chart of EPS (Diluted) of Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. EPS (Diluted) for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 -0.98 -1.0 -0.96
2020 -1.58 -1.02 -0.64 -0.62 -3.88
2019 -3.96 -9.3 -22.45
2018 -0.05

Business Profile of Phathom Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.